MediciNova (MediciNova) Price-to-Tangible-Book

: 1.44 (As of Today)

View and export this data going back to 2006. Start your Free Trial

As of today (2024-04-19), MediciNova's share price is $1.4099. MediciNova's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.98. Hence, MediciNova's Price to Tangible Book Ratio of today is 1.44.

The historical rank and industry rank for MediciNova's Price-to-Tangible-Book or its related term are showing as below:

MNOV' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.42 Med: 5.34 Max: 10.34
Current: 1.44

During the past 13 years, MediciNova's highest Price to Tangible Book Ratio was 10.34. The lowest was 1.42. And the median was 5.34.

MNOV's Price-to-Tangible-Book is ranked better than
73.34% of 1223 companies
in the Biotechnology industry
Industry Median: 2.7 vs MNOV: 1.44

A closely related ratio is called PB Ratio. As of today, MediciNova's share price is $1.4099. MediciNova's Book Value per Sharefor the quarter that ended in Dec. 2023 was $1.27. Hence, MediciNova's P/B Ratio of today is 1.11.

MediciNova Price-to-Tangible-Book Historical Data

The historical data trend for MediciNova's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediciNova Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

4.89

4.16

1.90

1.80

1.53

MediciNova Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book																1.80	1.99	2.22	2.04	1.53

Competitive Comparison

For the Biotechnology subindustry, MediciNova's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MediciNova Price-to-Tangible-Book Distribution

For the Biotechnology industry and Healthcare sector, MediciNova's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where MediciNova's Price-to-Tangible-Book falls into.

MediciNova Price-to-Tangible-Book Calculation

MediciNova's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	1.4099	/	0.978
	=	1.44

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

MediciNova Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of MediciNova's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

MediciNova (MediciNova) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediciNova Inc (NAS:MNOV) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

4875:Japan

Address

4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037

Website

https://www.medicinova.com

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.

Executives

Nicole Lemerond	director	3 MURRAY HILL ROAD, SCARSDALE NY 10583
Hideki Nagao	director	4350 LA JOLLA VILLAGE DRIVE, SUITE 950, SAN DIEGO CA 92122
Jason J Kruger	officer: Chief Financial Officer	4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Douglas Paulin	officer: Chief Financial Officer	4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Gaeta Federico C.a.	officer: Chief Scientific Officer	4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
3d Investment Partners Pte. Ltd.	10 percent owner	250 NORTH BRIDGE ROAD, #13-01 RAFFLES CITY TOWER, SINGAPORE U0 179101
3d Opportunity Master Fund	10 percent owner	C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Carolyn Beaver	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Stepanow Edward C Jr.	officer: Chief Financial Officer	4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Kazuko Matsuda	officer: Chief Medical Officer	C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Yuichi Iwaki	director	C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Carla Reyes	officer: Chief Financial Officer	4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Yoshio Ishizaka	director	4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Yutaka Kobayashi	director	4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Geoffrey Obrien	officer: Vice President	4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037